Donald J Trump (R) Sells Shares of Danaher Corporation
Trump's sale of Danaher shares was valued between $15,001 and $50,000.
Financial Disclosure Report
United States Congress • Office of Public Records • Washington, DC
Filer Information
- Name:
- Donald J Trump (R)
- Status:
- Member
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 1, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Danaher Corporation ($DHR) | Sell | May 22, 2026 | $15,001 - $50,000 |
Key Points
- Donald J Trump sold shares of Danaher Corporation valued between $15,001 and $50,000 on May 22, 2026.
- Danaher Corporation has a market cap of $134.8 billion and a forward P/E ratio of 20.68.
- Analysts have set price targets for Danaher, with the consensus rating being a strong buy.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Donald J Trump, the former U.S. President, sold shares of Danaher Corporation (NYSE:DHR) on May 22, 2026. The sale was valued between $15,001 and $50,000, as disclosed in a report filed on July 1, 2026. This transaction is part of the periodic reports required under the STOCK Act.
Donald J Trump vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Danaher Corporation Stock Down 11.7%
Shares of Danaher traded near $191.33 on Wednesday. The company, which operates in the healthcare sector, has a market capitalization of approximately $134.8 billion. Danaher's forward P/E ratio stands at 20.68, reflecting investor expectations for future earnings growth. The stock's 52-week range is between $160.93 and $242.80, with a 50-day moving average of $178.73 and a 200-day moving average of $203.94.
$DHR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Danaher reported revenue of about $24.78 billion, with a growth rate of 3.7%. The company's net margin is 14.9%, and it has a return on equity of 7.1%. The next earnings report is expected on July 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend of $1.60 per share, yielding 0.84%. The payout ratio is a moderate 26.36%, indicating a sustainable dividend policy.
Insider Buying and Selling at Danaher Corporation
On May 15, 2026, several insiders purchased shares of Danaher. Charles Lamanna, Shane Sanders, Linda Filler, and Alan Spoon each bought 1,699 shares, while Sanders and Filler also acquired an additional 680 shares each. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On June 11, 2026, Piper Sandler initiated coverage on Danaher with a hold rating and a $200 price target. Earlier, on June 3, HSBC maintained its buy rating, setting a target of $230. Citigroup reinstated a buy rating with a $230 target on May 27, while also downgrading the stock to hold with a $95 target on the same day. The consensus among analysts is a strong buy, with a mean target price of $242.35.
About Danaher Corporation
Danaher Corporation, headquartered in Washington, DC, designs and manufactures a wide range of products and services for professional, medical, research, and industrial applications. The company operates through its Biotechnology, Life Sciences, and Diagnostics segments, providing technologies and solutions that support the development and manufacture of therapeutics, diagnostic products, and research tools. Danaher employs around 58,000 people globally and is led by CEO Rainer M. Blair.
Bottom Line
Donald J Trump's sale of Danaher shares is a notable transaction given his public profile. Investors often keep an eye on such trades for potential insights, though these reports reflect past actions and not current positions. Danaher remains a significant player in the healthcare sector, with strong analyst support and a robust market presence.
Get Danaher Corporation alerts
New 13F filings, insider trades, and analyst moves on $DHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.